STOCK TITAN

SAB BIOTHERAPEUTICS INC - SABSW STOCK NEWS

Welcome to our dedicated page for SAB BIOTHERAPEUTICS news (Ticker: SABSW), a resource for investors and traders seeking the latest updates and insights on SAB BIOTHERAPEUTICS stock.

SAB Biotherapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a portfolio of products from its proprietary immunotherapy platform to produce targeted human polyclonal antibodies. The company leverages transchromosomic cattle genetically designed to produce human antibodies in response to an antigen. With a breakthrough therapy designation from the FDA, SAB-176 targets influenza strains, demonstrating sustained neutralization activity. The company's DiversitAb platform enables the production of fully human target-specific biologics for various therapeutic areas.

Rhea-AI Summary

SAB Biotherapeutics (Nasdaq: SABS) has appointed Lucy To as Chief Financial Officer, effective August 12, 2024. With over 18 years of investment banking and strategic operational expertise, Ms. To will lead corporate finance, strategy, and strategic business relationships at SAB. The company is developing human anti-thymocyte immunoglobulin (hIgG) to delay the onset or progression of type 1 diabetes (T1D).

SAB's CEO, Samuel J. Reich, expressed confidence in Ms. To's ability to contribute to the company's upcoming milestones for SAB-142, their lead candidate. Ms. To, previously a Managing Director in the Healthcare Investment Banking Group at Wells Fargo, brings extensive experience in M&A, IPOs, and other equity and debt financings in the healthcare sector, with transactions totaling over $50 billion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
News
Rhea-AI Summary

SAB Biotherapeutics, now rebranded as SAB BIO, has announced a new name, logo, and website updates. Despite the cosmetic changes, the company's stock symbol remains SABS. This rebranding aligns with SAB BIO's mission to address immune and autoimmune disorders, specifically type 1 diabetes (T1D), using their unique immunotherapy platform. CEO Samuel J. Reich emphasized the importance of this transformation in representing SAB BIO's focus on developing therapies to slow disease progression in T1D patients. The announcement comes ahead of their presentation at the American Diabetes Association 84th Scientific Sessions in Orlando. Additionally, the company reiterated its financial outlook for 2024 and upcoming milestones, including a Phase 1 study data readout for their lead candidate, SAB-142.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company, will present at the American Diabetes Association (ADA) 84th Scientific Sessions from June 21-24, 2024, in Orlando, Florida. The presentation will focus on SAB's novel immunotherapy platform, specifically its human anti-thymocyte immunoglobulin (hIgG) aimed at delaying the onset or progression of type 1 diabetes (T1D). Eric Sandhurst, Ph.D., SAB's Senior Program Manager, will present a poster on June 23, 2024, from 12:30 PM to 1:30 PM, detailing the IND-Enabling Assessment of Tolerance and Safety for SAB-142, a first-in-class fully human anti-thymocyte immunoglobulin. The poster will also be published online in the journal Diabetes® and available for viewing throughout the ADA sessions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary

SAB Biotherapeutics (Nasdaq: SABS) announced the departure of its Chief Financial Officer, Michael King, effective June 4, 2024. King is leaving to become CEO at a privately-held oncology company but will continue as an advisor to SAB until the end of the year. The company has initiated a search for his permanent replacement. In the interim, Mark Conley, Vice President of Finance, will serve as Interim CFO. SAB remains optimistic about its future, focusing on expanding its clinical programs, including the delay or progression of type 1 diabetes with its hIgG therapy. The company confirmed its 2024 financial outlook and upcoming milestones, including a Phase 1 data readout for SAB-142.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

SAB Biotherapeutics (Nasdaq: SABS) announced that the FDA has cleared its IND application for SAB-142, a type 1 diabetes therapy, to proceed to a Phase 1 clinical trial in the US.

SAB-142, a human anti-thymocyte immunoglobulin (hIgG), aims to delay the onset or progression of type 1 diabetes. The ongoing HUMAN trial will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of SAB-142 in both healthy volunteers and participants with type 1 diabetes.

The HUMAN trial is a randomized, double-blind, placebo-controlled, single-ascending dose study, with doses ranging from 0.03mg/kg to 2.5mg/kg. The trial design mimics the MELD-ATG study, whose topline results are expected in 2025.

The third cohort has been fully enrolled and dosed without observed serum sickness. This clearance marks a significant advancement in SAB's mission to slow disease progression in type 1 diabetes patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

SAB Biotherapeutics (Nasdaq: SABS) announced its Q1 2024 financial results and company updates. The company highlighted its focus on T1D immunotherapy, with significant progress in its SAB-142 program. Key pipeline milestones include the complete enrollment of the third cohort in its Phase 1 trial with no serum sickness observed and an impactful partnership with INNODIA. Financially, SAB reported a net loss of $4.0 million, a marked improvement from the $7.4 million loss in the previous year. Operating expenses increased, driven by higher R&D and G&A costs, reflecting intensified efforts in T1D research. Cash reserves stand at $45.2 million, anticipated to fund operations into 2026, assuming full exercise of outstanding warrants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

SAB Biotherapeutics announced the appointment of Dr. Jay Skyler to its Board of Directors. Dr. Skyler's expertise in type 1 diabetes research will benefit the company's SAB-142 program, focusing on delaying the onset of type 1 diabetes. With over five decades of experience in diabetes research, Dr. Skyler's contributions are expected to advance SAB's disease-modifying therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary
SAB Biotherapeutics, Inc. (Nasdaq: SABS) provides an update on the SAB-142 trial, reporting completion of dosing the third cohort with no observation of serum sickness. The Phase 1 clinical trial aims to investigate safety, tolerability, pharmacokinetics, and immunogenicity of SAB-142, a human anti-thymocyte immunoglobulin for delaying the onset or progression of type 1 diabetes (T1D).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
SAB Biotherapeutics, Inc. announced their Chief Medical Officer will share details on the SAB-142 clinical development plan at the INNODIA Annual Meeting. SAB is developing hIgG for delaying T1D onset or progression, positioning them as a key partner in the global T1D landscape.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary
SAB Biotherapeutics, Inc. (Nasdaq: SABS) announced CEO Samuel J. Reich will present at the 23rd Annual Needham Virtual Conference to discuss the company's hIgG therapy for type 1 diabetes. The presentation will cover SAB-142, a biologic for delaying diabetes onset, and partnership opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences

FAQ

What is the current stock price of SAB BIOTHERAPEUTICS (SABSW)?

The current stock price of SAB BIOTHERAPEUTICS (SABSW) is $0.03 as of February 25, 2025.

What is SAB Biotherapeutics Inc. focused on?

SAB is focused on developing and commercializing a portfolio of products from its immunotherapy platform to produce human polyclonal antibodies.

What is the novel DiversitAb platform used by SAB?

The DiversitAb platform enables the rapid production of targeted human polyclonal antibodies using transchromosomic cattle.

What is SAB-176 and its significance?

SAB-176 is a biologic targeting influenza strains with sustained neutralization activity and has received FDA Breakthrough Therapy Designation.

What is the focus of SAB's clinical programs?

SAB focuses on disease-modifying therapeutic approaches, such as SAB-142 targeting type 1 diabetes, aiming to prevent disease progression.

What are some key achievements of SAB in the clinical trials?

SAB has completed Phase 2 studies demonstrating the efficacy of its products in challenging influenza models, paving the way for potential breakthrough treatments.

How does SAB's immunotherapy platform differ from traditional methods?

SAB's platform leverages transchromosomic cattle to produce fully human antibodies, eliminating the need for convalescent plasma or human donors.

What is the significance of SAB's approach to human-specific biologics?

SAB's approach allows the production of highly targeted, high-potency, fully human IgGs to address serious unmet needs in various human diseases.

How does SAB aim to contribute to the field of immunotherapy?

SAB is committed to pioneering disease-modifying therapies, focusing on advancing treatments for immune and autoimmune disorders like type 1 diabetes.

How does SAB prioritize research and development efforts?

SAB's research and development efforts are geared towards developing safe, effective therapies with differentiated safety and immunogenicity profiles, aiming to change treatment paradigms in various diseases.

What future milestones can we expect from SAB?

SAB is on track to achieve upcoming milestones, including a Phase 2B trial for its lead candidate, SAB-142, and continued advancements in pioneering disease-modifying therapies.
SAB BIOTHERAPEUTICS INC

Nasdaq:SABSW

SABSW Rankings

SABSW Stock Data

9.23M
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
MIAMI BEACH